Navigation Links
Amicus Therapeutics Opens Research Facility in San Diego
Date:9/15/2008

CRANBURY, N.J. and SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that the company has leased laboratory space for a focused, small scale research facility in San Diego. The facility will be used to support ongoing research into new applications of the company's platform technology.

"With proof of concept for pharmacological chaperones now established, research at the San Diego facility will support Amicus' efforts to expand our early stage pipeline," said David Lockhart, Ph.D., chief scientific officer for Amicus Therapeutics. "Locating the new laboratory in San Diego allows us to complement and expand our existing research capabilities in Cranbury by tapping into the significant resources and expertise of the San Diego science and biotechnology community."

"We believe pharmacological chaperones have significant potential to treat a broad range of genetic diseases," added John Crowley, president and CEO of Amicus. "The focus of our research efforts in San Diego will be to assess new chaperone applications in diseases with high unmet medical needs and larger patient populations particularly in the areas of neurodegenerative and metabolic disorders. This small scale facility will complement our core research and development activities in New Jersey."

The new laboratory space was included in Amicus' operating plan and budget for 2008 as part of increased investment in research beyond the lysosomal storage disorders. Amicus expects to begin occupying the space immediately.

About Amicus Therapeutics

Amicus Therape
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... A ... discovered by researchers at the Keck Graduate Institute and its collaborators. The discovery ... The findings were published online on August 27 by Scientific Reports, an open ...
(Date:9/1/2015)... 2015 Shire plc (LSE: SHP, NASDAQ: ... to its Board of Directors as a Non-Executive Director. ... & Risk Committee of the Shire Board. Both appointments will ... previously served as Chairman, President and Chief Executive Officer of ... her 12-year tenure at D&B, she helped drive the transformation ...
(Date:8/31/2015)... ... August 31, 2015 , ... In recent years, biodegradable plastics ... low carbon footprints and compostability. These properties can help in limiting the degradation ... basis of applications, the market for biodegradable plastics can be broadly segmented into ...
(Date:8/31/2015)... 31, 2015 Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... The Mexico Biomedical Sensors market is estimated at $0.20 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
Breaking Biology Technology:Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Shire Appoints Sara Mathew to Board of Directors 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5Mexico Biomedical Sensors Market Report 2015-2020 2
... PITTSBURGH, Feb. 2, 2011 Forensic DNA profiling has ... people in the aftermath of mass violence and disaster, ... to identify and analyze the major ethical and policy ... (Logo: http://photos.prnewswire.com/prnh/20020422/CMULOGO) The National ...
... 2, 2011 New England Biolabs has expanded its ... generation sequencing to include NEBNext® Small RNA Sample Prep ... NEBNext Small RNA Sample Prep Set 3 for sequencing ... new and unique protocol, which results in higher yields ...
... N.M., Feb. 2, 2011 Elixir Bio-Tech Inc. (EBT), ... one of the top fifty winners of the FundingPost,s ... EBT is launching its Algae Biomass Feedstock project in ... multi-purpose feedstock with ground-breaking Proprietary and Patent Pending Technology ...
Cached Biology Technology:CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 2CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 3CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 4New England Biolabs Develops Novel Small RNA NGS Protocol: Reagents Improve Yield and Decrease Adaptor-Dimer Formation 2Elixir Bio-Tech Inc. Elected One of Top 50 Emerging Companies by 100 Venture Capital Funds & Angel Investors 2
(Date:8/6/2015)... SAN JOSE, Calif. , Aug. 6, 2015 ... the leading developer of human interface solutions, today ... and TouchPad technologies on Windows 10. Microsoft leveraged ... fundamental to the operating system. ... and drivers are fully certified with Microsoft,s Precision ...
(Date:8/4/2015)... ) today reported financial and operating results for the second quarter ... quarter contract revenue of $ 85.2 million, a ... of 26 % , Second quarter adjusted ... royalties in the current quarter , Operating cash ... to present another strong financial quarter, with all our divisions achieving ...
(Date:7/31/2015)... 2015 La 10e Conférence internationale sur ... par le BGI du 22 au 25 octobre ... Chine. La conférence célèbre son 10e ... l,ICG est devenue l,une des réunions annuelles mondiales ... et c,est aussi la plus dynamique, la plus ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... Voter Rolls and ... National ID Cards, ... Bulletin Board: BKYI), a leader in,finger-based biometric identification and wireless public ... prepackaged and customized software,solutions, today announced that they have been awarded ...
... the topping-out ceremony for the experimental hall of PETRA III ... Hamburg. On occasion of the structural completion of the building, ... Ole von Beust visited the Helmholtz research centre DESY. Its ... in 2009. PETRA III is a milestone on the ...
... A pasture improvement research program by Dr. Dariusz Malinowski ... an alternative to winter wheat pastures. But these ... parts of the nation, said Malinowski, a Texas Agricultural ... the Mediterranean Basin of southern Europe and northern Africa. ...
Cached Biology News:BIO-key(R) and Tiger IT Awarded a Follow-on Contract for Nationwide Voter / Citizen Registration in Bangladesh 2BIO-key(R) and Tiger IT Awarded a Follow-on Contract for Nationwide Voter / Citizen Registration in Bangladesh 3BIO-key(R) and Tiger IT Awarded a Follow-on Contract for Nationwide Voter / Citizen Registration in Bangladesh 4Brilliant perspectives 2Brilliant perspectives 3Summer-dormant tall fescue grass shows promise for pasture improvements 2Summer-dormant tall fescue grass shows promise for pasture improvements 3
... Antibody to Cytokeratin 5 / 6 ... molecular weight, basic type of cytokeratin expressed ... cell layers of stratified epithelia as well ... mesothelial cells and mesothelioma. Cytokeratin 6 (56 ...
Aldolase A (N-15)...
... Y2 Receptor antiserum This NPY Y2 ... level and is currently being characerized in brain. ... and mouse and appears to work better on ... rat. For full characterizarion in dorsal root ganglion ...
Black Polypropylene 384 Round Well Plate 70/Box...
Biology Products: